The AVID-CC trial will test the anti-tumor necrosis factor (anti-TNF) drug and will be aimed at treating people in the community, especially in care homes. It will enroll up to 750 patients from community care settings throughout the UK.
Oxford to study popular prescription drug as potential COVID-19 treatment
By REUTERS
11/25/2024 01:29 AM
By REUTERS
11/24/2024 09:11 PM
By REUTERS
11/24/2024 06:51 PM
By REUTERS
11/24/2024 05:13 PM
By REUTERS
11/24/2024 03:21 PM
By REUTERS
11/24/2024 01:09 PM